Explore Dulaglutide dosage trends, reconstitution volumes, and vial size patterns from anonymized WPA peptide calculator data.
Dulaglutide is a once-weekly GLP-1 receptor agonist developed by Eli Lilly, FDA-approved as Trulicity for type 2 diabetes in 2014. It is structurally distinct from peptide-class GLP-1 analogs: two GLP-1 analog peptide chains are covalently linked to a human IgG4-Fc fragment, producing a much larger ~63 kDa molecule with a ~5-day half-life.
Each of the two GLP-1 arms binds the GLP-1 receptor independently. The IgG4-Fc scaffold confers an extended half-life through FcRn recycling rather than albumin binding (the mechanism semaglutide and liraglutide use). The size of the fusion protein keeps it largely in the vascular compartment and limits CNS penetration, which has been hypothesized to contribute to its comparatively milder nausea profile.
The AWARD program established A1C reductions of ~1.4–1.6% at 1.5mg weekly across nine Phase 3 trials. REWIND (Gerstein et al., Lancet 2019) reported a 12% reduction in major adverse cardiovascular events in adults with T2D and a broad cardiovascular-risk profile — notably including a primary-prevention cohort, not just secondary-prevention. AWARD-11 demonstrated dose-response gains at 3.0mg and 4.5mg. Dulaglutide is the active comparator in the ongoing SURPASS-CVOT tirzepatide outcomes trial.
Dulaglutide has a reported half-life of ~5 days, and the dose intervals researchers model most often fall around once weekly. Long-acting GLP-1 designed for once-weekly dosing; it reaches a steady level in about 2–4 weeks, with a meaningful amount carrying over each week. It is catalogued under Weight Loss on WPA.
The WPA community has not yet logged enough Dulaglutide calculator sessions to publish dose, vial size, or bacteriostatic water distributions for it. This page therefore covers what is known about the compound itself; the usage charts fill in as researchers run the calculator.
These figures come from anonymized WPA peptide calculator sessions.
All figures shown are aggregated from anonymized calculator inputs and are provided strictly for independent laboratory research and educational purposes. They are community usage statistics — not dosing recommendations, and not medical advice.